By Eric Dutram of ETFdb
NEW YORK (TheStreet) -- Through almost six months, 2010 has not been kind to many of the world's largest companies, as a choppy market has given investors plenty of reasons to stay on the sidelines; debt issues threaten to drag down bank profits and a massive oil spill in the Gulf has sliced BP's shares nearly in half since the spill began almost six weeks ago (weighing on the entire sector in the process).
Meanwhile, an often overlooked situation is brewing at pharma giant Johnson & Johnson (JNJ), as the firm was recently forced to recall several children's pain and cold medicines over manufacturing issues which may have put metal particles into the products. Since hitting its 2010 high of just more than $66/share, J&J has plummeted more than 11.2% to its current share price of roughly $58.6/share, and some believe that the worst could still be ahead for the pharmaceutical giant.
The formal recall, announced on April 30, involved more than 136 million bottles of medicine, had metallic molecules and more active ingredients than approved. Moreover, the FDA found bacteria in some raw materials as well. This issue is likely to be dealt with easily by the gigantic firm but it could have long-term repercussions in terms of J&J's brand name power which is likely to suffer greatly from the incident. In addition to outrage from the public, many government officials are furious at the company for allegedly hiring a contractor to pose as consumers to buy the medicines in question rather than issue a formal recall.The FDA is now looking into criminal penalties against J&J with Joshua Sharfstein, the FDA's principal deputy commissioner, telling lawmakers at a hearing that J&J's McNeil Consumer Healthcare unit had a "pattern of noncompliance" and that regulators were considering "seizure, injunction or criminal penalties" in order to punish the firm. More recently, the House Committee on Oversight and Government Reform said that J&J had not met its 4 p.m. deadline for handing over the recall related documents and that the committee is mulling its next steps in order to get J&J to hand over the documents including subpoenaing them.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV